Trial · NCT03449251
Registered outcomes58
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 58
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Glucose) | Visit 2 to visit 4, over a period of up to 8 weeks | Glucose, in mmol/l |
| Primary | Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (C-Peptide) | Visit 2 to visit 4, over a period of up to 8 weeks | C-peptide, in pmol/L |
| Primary | Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Glucagon) | Visit 2 to visit 4, over a period of up to 8 weeks | Glucagon, in pg/ml |
| Primary | Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Insulin) | Visit 2 to visit 4, over a period of up to 8 weeks | Insulin, in pmol/L |
| Primary | Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (TNF-alpha) | Visit 2 to visit 4, over a period of up to 8 weeks | TNF-alpha, in pg/ml |
| Primary | Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants | Visit 2 to visit 5, over a period of up to 14 weeks | Glucose, in mmol/l |
| Primary | Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants | Visit 2 to visit 5, over a period of up to 14 weeks | C-peptide, in pmol/L |
| Primary | Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants | Visit 2 to visit 5, over a period of up to 14 weeks | Glucagon, in pg/ml |
| Primary | Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants | Visit 2 to visit 5, over a period of up to 14 weeks | Insulin, in pmol/L |
| Primary | Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants | Visit 2 to visit 5, over a period of up to 14 weeks | TNF-alpha, in pg/ml |
| Primary | Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Absolute Flow) | Within visit 2, over a period of up to 4 weeks | Absolute flow in the infused arm, in mg/dL/min |
| Primary | Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Percentage Change) | Within visit 2, over a period of up to 4 weeks | Percentage change in the infused arm, in % |
| Primary | Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Ratio) | Within visit 2, over a period of up to 4 weeks | Ratio, expressed as a number (no units as this is a ratio) |
| Primary | Sub-study 2b: Change in forearm blood flow parameters in healthy participants after infusion of relaxin in the presence of L-NMMA or normal saline | Visit 2 to visit 3, over a period of up to 10 weeks | Ratio; absolute flow and percentage change in the infused arm |
| Primary | Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Ratio) | Visit 2 to visit 3, over a period of up to 10 weeks | Ratio; expressed as a number (no units as this is a ratio) |
| Primary | Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Absolute Flow) | Visit 2 to visit 3, over a period of up to 10 weeks | Absolute flow in the infused arm, in mg/dL/min |
| Primary | Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Percentage Change) | Visit 2 to visit 3, over a period of up to 10 weeks | Percentage change in the infused arm, In % |
| Primary | Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin | Visit 2 to visit 3, over a period of up to 10 weeks | Ratio; absolute flow and percentage change in the infused arm |
| Primary | Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin (Ratio) | Visit 2 to visit 3, over a period of up to 10 weeks | Ratio, expressed as a number (no units as this is a ratio) |
| Primary | Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin (Absolute Flow) | Visit 2 to visit 3, over a period of up to 10 weeks | Absolute flow in the infused arm, in mg/dL/min |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03449251/registered